As a biotechnology company, Ligand Pharmaceuticals is engaged in the acquisition and licensing deals of royalty revenue-generating assets. The company claims to have one of the largest and most diverse portfolio of royalty-generating assets in the industry.

The therapies that they carry are promising treatments for patients that are suffering from a broad spectrum of diseases that remain to have a huge area of unmet medical needs. These maladies include multiple myeloma, dyslipidemia, osteoporosis, muscle wasting, anemia, fungal infection, diabetes and thrombocytopenia. These therapeutics are in various phases of clinical trials. In addition, they also have their Captisol platform technology involves a modified cyclodextrin that optimizes the stability and solubility of drugs.

To further expand its portfolio and to hasten the development of its candidate drugs, Ligan Pharmaceuticals maintains strategic partnership with leading companies like Merck, Pfizer, Onyx Pharmaceuticals, GlaxoSmithKline and Baxter International. The business is headquartered in La Jolla, California.